UPDATE: Dawson James Securities Downgrades SeraCare Life Sciences to Neutral

Dawson James Securities lowers its rate to Neutral on SeraCare Life Sciences

on the buyout of the company by a private equity firm. Dawson James Securities notes, "SeraCare has signed a definitive agreement to be acquired for $4.00 per share in cash by private equity firm Linden Capital Partners of Chicago. The deal, which has been approved by the Company's Board of Directors, is expected to close in calendar Q2/2012 (ending June 2012), following a vote by SeraCare's shareholders. Although the $4 price is below our current $5 price target, the price still represents a solid 30% premium over the price of SRLS shares at the start of the year and an approximate triple since our original recommendation in July 2009. We do not believe that a higher offer will be forthcoming." SRLS closed at $3.96 a share on Friday.